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Lung cancer is rich in molecular complex-
ities and driven by different abnormal 
molecular pathways. Personalised medicine 
has begun to bring new hope for the treat-
ment of patients with lung cancer, especially 
non-small cell lung cancer (NSCLC). The 
development of molecularly targeted therapy 
(small molecules and monoclonal anti-
bodies) has significantly improved outcomes 
in the metastatic setting for patients with 
NSCLC whose tumours harbour activated 
oncogenes such as epidermal growth factor 
receptor (EGFR) and translocated genes like 
anaplastic lymphoma kinase (ALK). In addi-
tion, immune checkpoint inhibitors have 
also dramatically changed the therapeutic 
landscape of NSCLC. In particular, mono-
clonal antibodies targeting the programmed 
death-1 receptor (PD-1) /PD ligand 1 
(PD-L1) pathway have emerged as powerful 
new therapeutic tools in several clinical trials, 
and some of them are already approved by 
the Food and Drug Administration (FDA) 
and American Medical Association (AMA). 
Immunotherapy is a novel type of treat-
ment that has been tested in patients with 
metastatic NSCLC. Two anti-PD-1 drugs 
(nivolumab and pembrolizumab) and one 
anti-PD-L1 drug (atezolizumab) have been 
approved as monotherapy for second-line 
treatment for NSCLC. Recent trials in first-
line treatment of advanced or metastatic 
NSCLC with nivolumab and pembrolizumab 
have shown promising and also controversial 
results. The FDA has approved pembroli-
zumab as a first-line treatment for patients 
with NSCLC whose tumours express PD-L1 
in more than 50% cells based on Keynote-
024 trial.1 This high PD-L1 presence is 
only observed on about 30% of patients 
with NSCLC, limiting the use of the newly 
approved drug in less than one-third newly 
diagnosed patients.
The results of nivolumab activity, in Check-
mate-26 study, compared with chemotherapy 
were disappointing.2 We are still trying to 
understand the possible reasons for the disap-
pointing progression-free survival (PFS) data 
and trying to find out how to improve survival 
with first-line immunotherapy. Either combi-
nation with chemotherapy, immunotherapy 
or newer investigational agents and a good 
biomarker may be tried.
Keynote-021 tested if the addition of 
pembrolizumab to the standard doublet 
chemotherapy (treatment with two chemo-
therapy drugs, either pemetrexed + platinum 
in adenocarcinoma or gemcitabine + plat-
inum in squamous cell lung carcinoma) 
improved outcomes compared with chemo-
therapy doublet alone.3 The results were 
published in November and showed that the 
trial had met its primary overall response 
rate (ORR) endpoint, with 55% ORR in the 
combination treatment group versus 29% 
in the chemotherapy-alone group. This 
trial accrued patients with different levels of 
PD-L1 expression, and as might have been 
expected, those with PD-L1 in more than 
50% of tumour cells had better responses to 
pembrolizumab + chemotherapy. Data from 
the Checkmate-012 trial have many drug 
combinations, and also combined nivolumab 
with different chemotherapy regimens in 
different types of NSCLC. The best response 
rate (47%) was observed in patients who 
received a combination of nivolumab with 
carboplatin and paclitaxel. Overall survival 
was also significantly improved for patients 
who received this combination treatment. 
PD-L1 expression appeared to play no role in 
treatment responses as per this study.
Several studies related to immunotherapy 
in NSCLC demonstrated that patients 
with EGFR mutations responded less to 
nivolumab and pembrolizumab. TATTON 
is a multi-arm phase Ib trial investigating 
osimertinib 80 mg in combination with 
durvalumab (anti-PD-L1 monoclonal anti-
body) in EGFR-mutant NSCLC.4 Part A was a 
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dose escalation study in patients with advanced NSCLC 
who had received prior treatment with an EGFR-tyrosine 
kinase inhibitor (TKI). Part B was a dose expansion trial 
conducted in patients with advanced disease who were 
EGFR-TKI treatment-naive. Part A included 21 patients 
receiving combination osimertinib plus durvalumab. 
Partial response (PR) was achieved by 12 patients, 9 
of them had confirmed PR. Stable disease (SD) was 
achieved by other nine patients. In part B, of ten patients 
with evaluable data, eight patients achieved PR, which 
was confirmed in seven patients, and SD was observed 
in two patients. Responses were durable and translated 
into remarkable long-term survival. Both arms noticed 
increased incidence of adverse events ranging from 
35% to 55%. Immunotherapy with EGFR-TKI combina-
tion appeared to have a good rational basis in terms of 
efficacy, relying on a presumption that a highly active 
therapy, such as an EGFR TKI in EGFR-mutant NSCLC, 
will lead to tumour apoptosis and enhanced immune 
priming, with resultant tumour lymphocytic infiltration 
and induced upregulation of PD-L1. But as explained 
by Gainor and colleagues from a limited number of 
patients with paired tumour specimens collected before 
and at the time of acquired resistance to TKI, they did 
not find clear changes in tumor-infiltrating lymphocytes 
(TILs) or PD-L1 expression.5 Besides, in the mentioned 
study of concomitant treatment with osimertinib and 
durvalumab, there was an increase in treatment-re-
lated adverse events especially in terms of pneumonitis; 
hence, this trial was stopped.
Regarding pharmacoeconomics in NSCLC, immu-
notherapy has a high economic impact for any health 
system.6 It is currently unknown for how long patients 
need to receive ‘checkpoint inhibition therapy’ in order 
to develop and sustain the appropriate immunological 
response. Pembrolizumab was approved as first-line treat-
ment for patients with metastatic NSCLC with high PD-1 
expression on October 24, becoming in 2016 the first 
immunotherapy drug to be ever approved as monotherapy 
for NSCLC. This approval has selected a restricted popu-
lation with EFGR/ALK wild-type and PD-L1 expression 
more than 50% as biomarker when pembrolizumab is 
used. How economically feasible is immunotherapy in all 
patients with high PD-L1 expression in NSCLC outside a 
clinical trial? Future trials will be necessary to address this 
question. Simply continuing therapy indefinitely once a 
response is attained may not be necessary when being 
treated with novel immunotherapy agents, as opposed 
to the more traditional chemotherapy drugs that have a 
short PFS (<6 months).
The FDA previously approved pembrolizumab only 
in patients whose tumours showed the presence of the 
PD-L1 protein in more than 1% of their cells, whereas 
nivolumab was approved regardless of PD-L1 status in 
second-line settings. Finally, in first-line treatment for 
patients with metastatic NSCLC, nivolumab failed at its 
primary endpoint (PFS in patients who expressed 5% 
PD-L1 or greater in tumour cells) when compared with 
pembrolizumab. The probable reasons are, first, the 
patients selected for participation in these trials were 
quite different from each other as more non-smokers 
were involved (11% vs 3%) in Checkmate-26 trial 
compared with Keynote-024. The second reason could 
be that the PD-L1 positivity (50% vs 30% in mentioned 
trails) cut-off values were different. Other reasons could 
be the variability of antibodies and immunohistochem-
ical procedures for positive criteria, heterogeneity of 
PD-L1 expression and the dynamic expression of PD-L1 
itself. Another aspect to consider is that in both studies, 
Checkmate-012 and Keynote-001, responses were higher 
in patients with KRAS mutations,7 so it is interesting to 
know that KRAS mutations seem to have increased PD-L1 
staining.
The FDA approval of two similar but distinct PD-L1 
immunohistochemistry (IHC) tests (22C3 pharmDx and 
28-8 pharmDx) acknowledges the potential of PD-L1 
as a predictive biomarker and helps physicians decide 
which checkpoint therapy to prescribe. Unfortunately, 
not all patients respond to these therapies, and evalua-
tion of biomarkers associated with clinical outcomes is 
crucial and ongoing.8 Also, the interpretation of PD-L1 
(IHC) testing results can be tricky and challenging. In 
connection with technical difficulties, we should consider 
that multiple staining methods and primary antibodies 
exist, with multiple cut-off when determining test posi-
tivity, and to all this preanalytical conditions must be 
added. This result in a high variability in staining perfor-
mance and multiple readouts. Moreover, in regard 
to biological issues, there is controversy over whether 
to consider tumour cells or immune cells or both, and we 
should also take into account the dynamic heterogeneity 
of PD-L1 IHC across the tumour sample. This last issue 
causes a failure to capture tumour complexity, with all its 
microenvironment.9
In their work Challenges & Perspective of Immuno-
therapy Biomarkers, Ung and Kockx propose a systematic 
application of a methodology, the HistoOncoImmune, 
which harnesses histopathology data of the tumour with 
its corresponding molecular signatures.10 The selected 
biomarkers are rigorously validated and can be imple-
mented across multiple clinical trials of various sizes 
and geographical locations. This system results in an 
integration of histopathology and molecular technology 
and provides investigators and physicians a method to 
understand the tumour microenvironment activity and 
its interface with the immune system. It offers a method-
ology to attain a biomarker profile that predicts response 
or resistance to immune checkpoint therapy.
In summary, considering the results of these trials, 
it seems that the place of immunotherapy in first-line 
treatment will be in combination with chemotherapy. 
Pembrolizumab has a definitive role in first-line treat-
ment for EGFR/EML-ALK4 wild-type NSCLC with 
PD-L1 expression more than 50%. The predictive 
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biomarkers that should be considered during single-
agent immunotherapy of NSCLC are PD-L1 expression 
50%, smoking, EGFR and ALK status, and KRAS muta-
tion positivity. To establish a clear cut-off value of PD-L1 
expression for appropriate immunological response 
and for new predictive biomarkers, further studies 
are required. Other important factors to be investi-
gated in future trials are for how long a patient needs 
to receive ‘checkpoint inhibition therapy’ to address 
pharmacoeconomics and sustain an appropriate immu-
nological response.
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